Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

phenformin

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Memorial Sloan-Kettering Cancer Center

Drug class:

mTOR inhibitor, AMPK activator

Related drugs:

‹

encapsulated rapamycin (0)

inhibitors of the PI3K/AKT/mTOR pathway (0)

albumin-bound (0)

metformin hydrochloride (0)

antroquinonol (0)

isoquercetin (0)

everolimus (138)

temsirolimus (37)

PF-05212384 (31)

GSK2126458 (17)

PF-04691502 (6)

niclosamide (1)

rapamycin topical (0)

ridaforolimus (0)

encapsulated rapamycin (0)

inhibitors of the PI3K/AKT/mTOR pathway (0)

albumin-bound (0)

metformin hydrochloride (0)

antroquinonol (0)

isoquercetin (0)

›

BRAF V600	Melanoma	BRAF V600	Melanoma	trametinib + dabrafenib + phenformin Sensitive: C3 – Early Trials trametinib + dabrafenib + phenformin Sensitive : C3	trametinib + dabrafenib + phenformin Sensitive: C3 – Early Trials trametinib + dabrafenib + phenformin Sensitive : C3
miR-17-HG overexpression + MYC positive	Lymphoma	miR-17-HG overexpression + MYC positive	Lymphoma	phenformin Sensitive: D – Preclinical phenformin Sensitive : D	phenformin Sensitive: D – Preclinical phenformin Sensitive : D
miR-17-HG expression + MYC positive	Lymphoma	miR-17-HG expression + MYC positive	Lymphoma	phenformin Sensitive: D – Preclinical phenformin Sensitive : D	phenformin Sensitive: D – Preclinical phenformin Sensitive : D
miR-17-HG deletion + MYC positive	Lymphoma	miR-17-HG deletion + MYC positive	Lymphoma	phenformin Resistant: D – Preclinical phenformin Resistant : D	phenformin Resistant: D – Preclinical phenformin Resistant : D